Equities Analysts Offer Predictions for PBH Q4 Earnings

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Equities research analysts at Zacks Research increased their Q4 2026 EPS estimates for Prestige Consumer Healthcare in a research report issued on Tuesday, February 24th. Zacks Research analyst Team now expects that the company will earn $1.59 per share for the quarter, up from their prior estimate of $1.54. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.50 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare’s Q3 2027 earnings at $1.21 EPS, Q4 2027 earnings at $1.32 EPS and Q1 2028 earnings at $1.14 EPS.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings data on Thursday, February 5th. The company reported $1.14 earnings per share for the quarter, missing the consensus estimate of $1.16 by ($0.02). The company had revenue of $283.44 million during the quarter, compared to the consensus estimate of $286.93 million. Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.The business’s revenue for the quarter was down 2.4% on a year-over-year basis. During the same quarter last year, the firm earned $1.22 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS.

PBH has been the topic of a number of other reports. Canaccord Genuity Group cut their target price on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating on the stock in a research report on Friday, November 7th. Weiss Ratings reissued a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Thursday, January 22nd. Finally, Jefferies Financial Group reduced their price objective on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating on the stock in a research note on Friday, January 30th. Three investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $80.60.

Prestige Consumer Healthcare Trading Up 0.8%

Shares of PBH opened at $69.36 on Thursday. The stock’s fifty day simple moving average is $64.95 and its 200-day simple moving average is $63.40. The company has a quick ratio of 1.93, a current ratio of 3.11 and a debt-to-equity ratio of 0.58. The firm has a market capitalization of $3.28 billion, a PE ratio of 18.35, a price-to-earnings-growth ratio of 2.16 and a beta of 0.43. Prestige Consumer Healthcare has a 12-month low of $57.25 and a 12-month high of $90.04.

Insider Transactions at Prestige Consumer Healthcare

In related news, VP Jeffrey Zerillo sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $65.93, for a total value of $65,930.00. Following the completion of the sale, the vice president directly owned 41,048 shares in the company, valued at approximately $2,706,294.64. This trade represents a 2.38% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last three months, insiders have sold 2,000 shares of company stock valued at $125,930. Company insiders own 1.40% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in PBH. Dean Capital Management bought a new stake in Prestige Consumer Healthcare in the 4th quarter valued at $2,523,000. Invesco Ltd. increased its holdings in shares of Prestige Consumer Healthcare by 7.5% in the fourth quarter. Invesco Ltd. now owns 584,021 shares of the company’s stock valued at $36,028,000 after purchasing an additional 40,950 shares during the last quarter. State of Tennessee Department of Treasury grew its stake in Prestige Consumer Healthcare by 2.8% in the 4th quarter. State of Tennessee Department of Treasury now owns 16,049 shares of the company’s stock valued at $1,035,000 after buying an additional 435 shares during the last quarter. XTX Topco Ltd bought a new position in Prestige Consumer Healthcare in the 4th quarter valued at about $2,624,000. Finally, Millennium Management LLC lifted its position in Prestige Consumer Healthcare by 72.5% during the fourth quarter. Millennium Management LLC now owns 31,099 shares of the company’s stock worth $1,918,000 after acquiring an additional 13,069 shares during the last quarter. 99.95% of the stock is currently owned by institutional investors.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).